These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8545255)

  • 21. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.
    Maccario M; Arvat E; Procopio M; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1995 Jan; 44(1):134-8. PubMed ID: 7854159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).
    Laron Z; Frenkel J; Gil-Ad I; Klinger B; Lubin E; Wuthrich P; Boutignon F; Lengerts V; Deghenghi R
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):539-41. PubMed ID: 7955465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hexarelin stimulation of growth hormone release and mRNA levels in an infant and adult rat model of impaired GHRH function.
    Torsello A; Luoni M; Grilli R; Guidi M; Wehrenberg WB; Deghenghi R; Müller EE; Locatelli V
    Neuroendocrinology; 1997 Feb; 65(2):91-7. PubMed ID: 9067986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E; Gianotti L; Di Vito L; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The sequential administration of growth hormone-releasing hormone followed 120 minutes later by hexarelin, as an effective test to assess the pituitary GH reserve in man.
    Micic D; Popovic V; Kendereski A; Peino R; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):543-51. PubMed ID: 8977750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of body composition on hexarelin-induced growth hormone release in normal elderly subjects.
    Rahim A; O'Neill P; Shalet SM
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):659-64. PubMed ID: 10197083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic extraction of hexarelin, a new peptidic GH secretagogue, in the isolated perfused rat liver.
    Roumi M; Marleau S; Boghen M; Nilsson M; Du Souich P; Ong H
    Pharm Res; 1997 Aug; 14(8):1008-13. PubMed ID: 9279881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery.
    Broglio F; Guarracino F; Benso A; Gottero C; Prodam F; Granata R; Avogadri E; Muccioli G; Deghenghi R; Ghigo E
    Eur J Pharmacol; 2002 Jul; 448(2-3):193-200. PubMed ID: 12144941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.
    Rossoni G; Locatelli V; Gennaro Colonna Vd ; Müller EE; Berti F
    Pharmacol Res; 2000 Aug; 42(2):129-36. PubMed ID: 10887041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man.
    Arosio M; Casati G; Biella O; Porretti S; Imbimbo BP; Faglia G
    J Endocrinol Invest; 1998 Apr; 21(4):239-44. PubMed ID: 9624598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
    Korbonits M; Kaltsas G; Perry LA; Putignano P; Grossman AB; Besser GM; Trainer PJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2489-95. PubMed ID: 10404825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth hormone secretagogue (GHS) analogue, hexarelin stimulates GH from peripheral lymphocytes.
    Poppi L; Dixit VD; Baratta M; Giustina A; Tamanini C; Parvizi N
    Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):343-7. PubMed ID: 12397533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man.
    Arvat E; Gianotti L; Ramunni J; DiVito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1996 Jan; 19(1):25-9. PubMed ID: 8851688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers.
    Frieboes RM; Antonijevic IA; Held K; Murck H; Pollmächer T; Uhr M; Steiger A
    Psychoneuroendocrinology; 2004 Aug; 29(7):851-60. PubMed ID: 15177700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprikalim: radioimmunoassay and pharmacokinetic studies in mouse, monkey, and dog.
    Chevalier P; Rouillard C; Montay G; Frydman A
    J Pharm Sci; 1994 Mar; 83(3):372-8. PubMed ID: 8207684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency.
    De Gennaro Colonna V; Rossoni G; Bernareggi M; Müller EE; Berti F
    Cardiologia; 1997 Nov; 42(11):1165-72. PubMed ID: 9534309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.
    Huang J; Li Y; Zhang J; Liu Y; Lu Q
    Int Heart J; 2017 Apr; 58(2):257-263. PubMed ID: 28321024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a sensitive radioimmunoassay for Fab fragments: application to Fab pharmacokinetics in humans.
    Thanh-Barthet CV; Urtizberea M; Sabouraud AE; Cano NJ; Scherrmann JM
    Pharm Res; 1993 May; 10(5):692-6. PubMed ID: 8321833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disposition of growth hormone-releasing peptide (SK&F 110679) in rat and dog following intravenous or subcutaneous administration.
    Davis CB; Crysler CS; Boppana VK; Fong KL; Joseph GL; Urbanski JJ; Macia RA; Rhodes GR
    Drug Metab Dispos; 1994; 22(1):90-8. PubMed ID: 8149896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.